Semaglutide vs Dulaglutide for Weight Loss: Which GLP-1 Works Better?

Maria had been taking dulaglutide for her type 2 diabetes for nearly a year when she noticed something interesting at her support group. Three other members had recently switched to semaglutide, and all of them were losing significantly more weight than she was. "I thought all these GLP-1 medications were basically the same," she told her doctor at her next visit. "But now I'm wondering if I'm missing out on something."

She's not alone in this confusion. While semaglutide and dulaglutide belong to the same class of medications—both are GLP-1 receptor agonists—their weight loss profiles differ substantially. The data from head-to-head comparisons and major clinical trials reveals some pretty clear distinctions that can make a real difference in your results.

How These Two GLP-1 Medications Compare in Clinical Studies

Let's start with what matters most: the numbers. In the landmark STEP 1 trial, participants taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. That's nearly 15% of your starting weight. For someone weighing 220 pounds, that translates to roughly 33 pounds lost.

Dulaglutide's weight loss data tells a different story. In the AWARD trials that led to its FDA approval, participants lost between 3-5 pounds on average at the highest dose (1.5 mg). Even in longer studies specifically looking at weight outcomes, dulaglutide users typically see about 3-5% body weight reduction. That's still clinically meaningful, but it's nowhere near what we observe with semaglutide.

The SUSTAIN-7 trial provided a direct comparison that settled the debate. This head-to-head study matched semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg in people with type 2 diabetes. After 40 weeks, those taking semaglutide 1.0 mg lost an average of 11 pounds, while dulaglutide 1.5 mg users lost about 6.6 pounds. That's nearly double the weight loss with semaglutide.

Why such a dramatic difference? Both medications work by mimicking GLP-1, a hormone that regulates blood sugar and appetite. But semaglutide has a longer half-life—about seven days compared to dulaglutide's roughly five days. This extended duration means more consistent appetite suppression throughout the week. Semaglutide also appears to have stronger binding affinity to GLP-1 receptors, which may explain its more pronounced effects on both weight and blood sugar control.

It's worth noting that dulaglutide was never specifically approved for weight loss by the FDA. It's a diabetes medication that happens to cause some weight reduction as a beneficial side effect. Semaglutide, on the other hand, received separate FDA approval specifically for chronic weight management in 2021 under the brand name Wegovy at the 2.4 mg dose. That distinction reflects the substantial difference in their weight loss efficacy.

Side Effects and Tolerability: What to Expect

Both medications share a similar side effect profile because they work through the same biological pathway. Gastrointestinal symptoms top the list for both drugs. We're talking nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects typically appear when you first start the medication or increase your dose.

Here's where things get interesting: despite producing more dramatic weight loss, semaglutide doesn't necessarily cause worse side effects than dulaglutide. In the SUSTAIN-7 trial, discontinuation rates due to adverse events were actually similar between the two medications—about 6-7% of participants stopped treatment because of side effects, regardless of which drug they were taking.

The nausea rates differ slightly. In clinical trials, about 20-25% of people taking semaglutide reported nausea, compared to roughly 15-20% with dulaglutide. But here's the important part: for most people, these symptoms are temporary. They typically peak during the first few weeks after starting or dose escalation, then gradually improve as your body adjusts. We see this pattern consistently in our clinical experience.

Both medications require a slow titration schedule precisely to minimize these gastrointestinal effects. You'll start at a low dose and gradually increase every four weeks. This gives your digestive system time to adapt. Semaglutide typically starts at 0.25 mg weekly for four weeks, then 0.5 mg, then 1.0 mg, and potentially up to 2.4 mg for weight loss. Dulaglutide usually begins at 0.75 mg weekly and may increase to 1.5 mg after four weeks.

One practical difference: the injection devices themselves. Dulaglutide comes in a pre-filled, single-dose pen that some patients find easier to use—you just press a button and hold it against your skin. Semaglutide pens require you to attach a needle and dial your dose, which gives more flexibility but involves an extra step. Neither injection is particularly painful; both use small needles injected into the fatty tissue of your abdomen, thigh, or upper arm.

Serious side effects remain rare with both medications but include potential risks like pancreatitis, gallbladder problems, and thyroid tumors (seen in animal studies but not confirmed in humans). Both carry the same black box warning about thyroid C-cell tumors and shouldn't be used if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Cost Considerations and Insurance Coverage

This is where the conversation gets frustrating for many patients. Brand-name Ozempic (semaglutide for diabetes) typically costs around $900-$1,000 per month without insurance. Wegovy (semaglutide for weight loss) runs similarly expensive. Dulaglutide's brand name Trulicity costs roughly $800-$900 monthly without coverage.

Insurance coverage creates a complicated landscape. If you have type 2 diabetes, many insurance plans will cover both medications as diabetes treatments. Your out-of-pocket cost might range from $25 to $100 per month with commercial insurance, though this varies wildly depending on your specific plan and whether these drugs are on your formulary.

Weight loss coverage is another story entirely. Most insurance companies still don't cover GLP-1 medications prescribed solely for obesity or weight management, even though obesity is a recognized medical condition. You might have diabetes coverage for Ozempic but no coverage for Wegovy at the weight-loss dose, even though it's the same medication. Medicare doesn't cover weight loss medications at all due to a federal law from 2003, though there's ongoing advocacy to change this.

This coverage gap has created a surge in compounded semaglutide and tirzepatide options. Compounded versions, prepared by specialized pharmacies, can cost $200-$400 per month—still expensive, but more accessible than brand-name versions for people paying out of pocket. Compounded dulaglutide is less common in the market simply because demand has shifted toward the more effective weight loss options.

Manufacturer savings programs can help if you don't have insurance coverage. Both Novo Nordisk (maker of semaglutide) and Eli Lilly (maker of dulaglutide) offer patient assistance programs that might reduce your monthly cost to $25 if you qualify. However, these programs typically exclude people on Medicare or Medicaid and have income restrictions.

Who Should Choose Which Medication?

Your individual situation matters more than any general recommendation. If you have type 2 diabetes and need both blood sugar control and weight loss, semaglutide generally provides superior results on both fronts. The SUSTAIN trials showed A1C reductions of 1.5-1.8% with semaglutide compared to 1.1-1.4% with dulaglutide. That difference might not sound huge, but it can determine whether you reach your target A1C or need additional medications.

For people focused primarily on weight loss (with or without diabetes), semaglutide is the clear winner based on clinical evidence. The 10-15% weight loss typically seen with semaglutide 2.4 mg can produce meaningful improvements in obesity-related conditions like sleep apnea, joint pain, fatty liver disease, and cardiovascular risk factors.

That said, dulaglutide might make sense for certain patients. If you've tried semaglutide and couldn't tolerate the side effects, dulaglutide could be worth trying—some people do better with its slightly different pharmacokinetic profile. If your insurance covers dulaglutide but not semaglutide, and you need help with blood sugar control plus modest weight loss, it's certainly a reasonable option. And if you're particularly needle-averse, dulaglutide's single-button injection device might feel less intimidating.

We also consider your weight loss goals. Someone who needs to lose 15-20 pounds might do fine with dulaglutide, especially if they're also making significant lifestyle changes. Someone with 50+ pounds to lose will likely need the stronger effects of semaglutide (or tirzepatide, which we often recommend as an even more effective option than semaglutide).

What Women Should Know

Both medications affect women and men similarly in terms of weight loss efficacy, but there are some gender-specific considerations. If you're of childbearing age, you need to know that significant weight loss can increase fertility—we've seen patients get unexpectedly pregnant after starting GLP-1 therapy because their PCOS symptoms improved or ovulation resumed.

Neither semaglutide nor dulaglutide is recommended during pregnancy. You should use reliable contraception while taking either medication and stop the drug at least two months before trying to conceive. The good news: GLP-1 medications can improve metabolic parameters that affect fertility, so many women find it easier to conceive after losing weight and then stopping the medication.

Some women report that gastrointestinal side effects feel worse around their menstrual cycle, possibly due to hormonal fluctuations affecting gut motility. This isn't unique to GLP-1 medications, but it's worth noting. Adjusting your dose timing or being extra careful with trigger foods during this time can help manage symptoms.

What Men Should Know

Men typically start at higher body weights and often see larger absolute weight loss numbers, though the percentage of body weight lost remains similar between genders. The cardiovascular benefits of GLP-1 medications might be particularly relevant for men, who face higher baseline cardiovascular risk.

The SELECT trial, which specifically studied semaglutide's cardiovascular effects, showed a 20% reduction in major cardiac events. This included reduced risk of heart attack, stroke, and cardiovascular death. While the trial included both men and women, men made up the majority of participants, and the protective effects were consistent.

There's also emerging evidence that weight loss from GLP-1 medications can improve testosterone levels in men with obesity. Many of our male patients report improved energy, mood, and sexual function after losing weight on these medications, though it's hard to separate the direct effects of weight loss from any medication-specific benefits.

From the Ozari Care Team

We see patients wrestling with this comparison weekly, and here's what we tell them: if your primary goal is weight loss and you can access semaglutide, that's typically where we start. The superior weight loss data speaks for itself. We do emphasize that success with any GLP-1 medication depends on more than just the prescription—you'll get the best results by combining medication with sustainable nutrition changes and regular movement. These medications are powerful tools that reduce hunger and cravings, but they work best as part of a broader approach to metabolic health. We're here to support you through the entire process, from managing side effects to celebrating your progress.

Key Takeaways

• Semaglutide produces approximately three times more weight loss than dulaglutide—around 15% body weight reduction versus 3-5% in clinical trials
• Both medications share similar side effect profiles, primarily gastrointestinal symptoms that typically improve after the first few weeks
• Semaglutide is FDA-approved specifically for weight loss (as Wegovy) while dulaglutide is only approved for type 2 diabetes management
• Insurance coverage for weight loss remains challenging with both medications, though compounded options have made semaglutide more accessible
• For patients with type 2 diabetes who need both blood sugar control and weight loss, semaglutide generally provides superior results on both measures

Frequently Asked Questions

Can I switch from dulaglutide to semaglutide?

Yes, switching between these medications is common and generally straightforward. Most providers will have you take your last dose of dulaglutide, then start semaglutide at the lowest dose (0.25 mg) within a week. Because dulaglutide stays in your system for several days, there's usually enough overlap to prevent any gap in coverage. You'll still need to follow the standard titration schedule with semaglutide, starting low and gradually increasing, even though you're already accustomed to a GLP-1 medication. Some patients experience fewer side effects when switching compared to starting from scratch, but this isn't guaranteed.

Will I gain the weight back if I stop taking either medication?

This is one of the most common concerns we hear, and it's a fair question. Studies show that many people do regain weight after stopping GLP-1 medications—the STEP 1 trial extension found that participants regained about two-thirds of their lost weight within a year of stopping semaglutide. However, this isn't inevitable. People who use the medication period to build sustainable nutrition and exercise habits, address emotional eating patterns, and make lasting lifestyle changes often maintain more of their weight loss. Think of these medications as tools that give you a window of reduced hunger and cravings to establish healthier patterns that can continue after you stop.

How quickly will I see weight loss results with each medication?

You'll likely notice weight loss within the first month on either medication, though semaglutide typically produces faster and more noticeable results. Most patients lose 5-8 pounds in the first month on semaglutide, while dulaglutide users might see 2-4 pounds initially. The weight loss continues as you increase to higher doses, with the most dramatic results typically occurring between months 3-8. Remember that weight loss isn't perfectly linear—you might see weeks with no change followed by weeks with larger drops. This is completely normal and doesn't mean the medication has stopped working.

Do these medications work if I don't have diabetes?

Absolutely. Semaglutide received FDA approval specifically for weight management in people without diabetes, based on the STEP clinical trial program that included participants without diabetes. The medication works by reducing appetite and slowing stomach emptying, which helps anyone eat less—regardless of diabetes status. In fact, some research suggests the weight loss might be slightly more pronounced in people without diabetes, possibly because they don't have the metabolic challenges that come with longstanding diabetes. Dulaglutide hasn't been formally studied or approved for weight loss in non-diabetics, though the mechanism would theoretically work similarly.

Can I take a lower dose long-term instead of increasing to the maximum?

Yes, and many patients do exactly this. While the clinical trials used standardized escalation schedules, real-world treatment is more flexible. If you're getting good results and tolerating a particular dose well, there's no requirement to keep increasing. Some people find their sweet spot at 0.5 mg or 1.0 mg of semaglutide and stay there indefinitely. Others need the full 2.4 mg dose to achieve their goals. The right dose is the one that gives you meaningful results with tolerable side effects. We work with patients individually to find that balance, and it's perfectly fine to stay at a lower maintenance dose once you've reached your target weight or found a dose that works well for you.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, shipped to your door. Learn more at ozarihealth.com.